LCT starts Phase IIb clinical trial of NTCELL
Filed with ASX · · 3 pages · English
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- LCT completes $2.8m private placement and announces SPP
- LCT receives ethics approval for Phase IIb Parkinsons trial
- NTCELL reverses the progression of Parkinsons disease
Later from Algorae Pharmaceuticals
- LCT JV secures funds to realise the potential of DIABECELL
- NTCELL demonstrates continued reversal of Parkinsons
- LCTs joint venture focuses on US developments
- Group 1 patients successfully treated in Parkinsons trial
- Appendix 4C Quarterly Cash Flow Report 30 September 2016
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals